⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma

Official Title: Randomized Feasibility Study Of Active Symptom Control With Or Without Chemotherapy In The Treatment Of Patients With Mesothelioma

Study ID: NCT00030459

Study Description

Brief Summary: RATIONALE: Palliative therapy may help patients with advanced cancer live more comfortably. It is not yet known if palliative therapy is more effective with or without chemotherapy in treating patients who have malignant mesothelioma. PURPOSE: Randomized phase II trial to compare the effectiveness of palliative therapy with or without different chemotherapy regimens in treating patients who have malignant mesothelioma.

Detailed Description: OBJECTIVES: * Determine the feasibility of palliative therapy alone versus palliative therapy with mitomycin, vinblastine, and cisplatin versus palliative therapy with vinorelbine in patients with malignant mesothelioma. * Determine the quality of life of patients treated with these regimens. OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of three treatment arms. * Arm I: Patients receive palliative therapy alone comprising non-chemotherapeutic therapy (e.g., radiotherapy, painkillers, steroids, relaxants, and special pain relief techniques). * Arm II: Patients receive palliative therapy as in arm I and chemotherapy comprising mitomycin IV (courses 1, 2, and 4 only), vinblastine IV, and cisplatin IV over 4 hours on day 1. Chemotherapy repeats every 21 days for a total of 4 courses. * Arm III: Patients receive palliative therapy as in arm I and chemotherapy comprising vinorelbine IV over 5 minutes once weekly on weeks 1-6 and 9-14. Quality of life is assessed at baseline for all patients; at weeks 3, 6, 9, and 12 for arm I; at weeks 4, 7, 10, and 13 for arm II; at weeks 3, 6, 10, and 13 for arm III; at weeks 21 and 29, and then every 8 weeks thereafter for all patients. Patients are followed every 8 weeks. PROJECTED ACCRUAL: A total of 60 patients (20 per treatment arm) will be accrued for this study within 1 year.

Eligibility

Minimum Age:

Eligible Ages: CHILD, ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Princess Royal Hospital, Hull, England, United Kingdom

Leeds Teaching Hospital Trust, Leeds, England, United Kingdom

Saint Bartholomew's Hospital, London, England, United Kingdom

Medical Research Council Clinical Trials Unit, London, England, United Kingdom

Royal Marsden Hospital, Sutton, England, United Kingdom

Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom

Stobhill General Hospital, Glasgow, Scotland, United Kingdom

Dorothy House Foundation, Bradford-Onavon, , United Kingdom

St. Peters Hospital, Chertsey Surrey, , United Kingdom

Contact Details

Name: Martin F. Muers, MD

Affiliation: Leeds General Infirmary

Role: STUDY_CHAIR

Name: David J. Girling, MD

Affiliation: Medical Research Council

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: